Komori
Share Issuance and Disposal4890Tsubota Laboratory IncorporatedPharmaceuticals

Notice of Completion of Payment for the 8th, 9th and 10th Stock Acquisition Rights Issued Through Third-Party Allotment

The allotment of the 8th through 10th Series of Stock Acquisition Rights with options to adjust the exercise price to Cantor Fitzgerald Europe and the related payments have been completed. Exercise of the rights is expected to result in the issuance of up to 5,904,600 new shares and net proceeds of approximately ¥1,989,059,662. The actual amount raised will vary depending on the exercise status and adjustments to the exercise price.

Worth reading
68In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
5904600
Shares (potential shares)
Wording
Avoiding a definitive answer
How definitive the wording is.

Details of issuance or disposal

8th Series Stock Acquisition Rights through a third-party allotment (with an option to adjust the exercise price), 9th Series Stock Acquisition Rights (with an option to adjust the exercise price), and 10th Series Stock Acquisition Rights (with an option to adjust the exercise price)

Who receives how much

24,561 8th Series Stock Acquisition Rights (potential shares: 2,456,100), 20,467 9th Series Stock Acquisition Rights (potential shares: 2,046,700), and 14,018 10th Series Stock Acquisition Rights (potential shares: 1,401,800), for a total of 59,046 rights (potential shares: 5,904,600)

Cantor Fitzgerald Europe (59,046 rights)

The lower thin line represents the existing number of shares to which these shares will be added.

¥77 per Series 8 stock acquisition right, ¥71 per Series 9 stock acquisition right, and ¥56 per Series 10 stock acquisition right
Total issue value

¥4,129,362

Amount of funds to be raised
¥2,004,059,662 (estimated net proceeds: ¥1,989,059,662)
Estimated issuance expenses
¥15,000,000
Terms of the stock acquisition rights
Exercise price
The initial exercise prices are ¥285 for the 8th Series, ¥342 for the 9th Series and ¥428 for the 10th Series. They may be adjusted by resolution of the Board of Directors, with the adjusted exercise price set at approximately 90% of the closing price on the final trading day of the week preceding the week in which the adjustment date falls. The minimum exercise price is ¥127.5.
Exercise period
18 June 2026 to 15 June 2029
Number of Stock Acquisition Rights
Total issued: 59,046 rights. Unexercised balance: Not disclosed.
Payment date
17 June 2026
Procedures under the Corporate Code of Conduct
The Company will implement restrictions on the exercise of these Stock Acquisition Rights in accordance with Article 434, Paragraph 1 of the TSE Securities Listing Regulations and Article 436, Paragraphs 1 through 5 of the Enforcement Rules thereof, as well as the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters.
Details of issuance or disposal
ItemDetails
Type of issuance or disposal8th Series Stock Acquisition Rights through a third-party allotment (with an option to adjust the exercise price), 9th Series Stock Acquisition Rights (with an option to adjust the exercise price), and 10th Series Stock Acquisition Rights (with an option to adjust the exercise price)
Number of shares to be issued or disposed of24,561 8th Series Stock Acquisition Rights (potential shares: 2,456,100), 20,467 9th Series Stock Acquisition Rights (potential shares: 2,046,700), and 14,018 10th Series Stock Acquisition Rights (potential shares: 1,401,800), for a total of 59,046 rights (potential shares: 5,904,600)
Issue price and disposal price¥77 per Series 8 stock acquisition right, ¥71 per Series 9 stock acquisition right, and ¥56 per Series 10 stock acquisition right
Total issue value¥4,129,362
Amount of funds to be raised¥2,004,059,662 (estimated net proceeds: ¥1,989,059,662)
Estimated issuance expenses¥15,000,000
Payment date17 June 2026
Intended allotteeCantor Fitzgerald Europe (59,046 rights)
Exercise priceThe initial exercise prices are ¥285 for the 8th Series, ¥342 for the 9th Series and ¥428 for the 10th Series. They may be adjusted by resolution of the Board of Directors, with the adjusted exercise price set at approximately 90% of the closing price on the final trading day of the week preceding the week in which the adjustment date falls. The minimum exercise price is ¥127.5.
Exercise period18 June 2026 to 15 June 2029
Number of Stock Acquisition RightsTotal issued: 59,046 rights. Unexercised balance: Not disclosed.
Procedures under the Corporate Code of ConductThe Company will implement restrictions on the exercise of these Stock Acquisition Rights in accordance with Article 434, Paragraph 1 of the TSE Securities Listing Regulations and Article 436, Paragraphs 1 through 5 of the Enforcement Rules thereof, as well as the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters.
Items this document does not state (16)
Specific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company states that it may exercise the option to adjust the exercise price when it determines that doing so is necessary for financing purposes. It also explains that adjusting the exercise price weekly will mitigate the impact of short-term share price fluctuations on the likelihood of exercise, while securing the benefit of raising funds at a higher exercise price when the share price rises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the 8th, 9th and 10th Stock Acquisition Rights Issued Through Third-Party Allotment | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori